$HOWL

RA CAPITAL MANAGEMENT, L.P. sold $174K of HOWL (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 448,836 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.39 ($0.37–$0.40, $0.17M total) across 6 trades over 2026-06-12 to 2026-06-16.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jun 16, 2026, 10:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HOWL
Neutral
medium confidence
Mentioned
$HOWL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HOWLNeutralLow
01

Why it matters

The newest concrete fact is the disclosed open-market sale size, price range, and post-transaction share count; it can influence short-term sentiment but does not introduce new operational or regulatory information.

02

Market read

Traders may monitor for follow-on selling/position changes, but the filing alone is unlikely to drive a durable repricing without accompanying fundamental catalysts.

03

What to watch

Because the trades occurred across multiple days and the filing is after the fact, the market may already have partially priced any immediate signal; also, indirect holdings can be less informative than direct insider sales.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-16 (after the June 12–16 sale window).

Background

The article is an SEC Form 4 insider transaction disclosure for Werewolf Therapeutics (HOWL), reported by RA Capital Management, L.P. as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$HOWLNeutralMedium confidence
Context

RA Capital Management, a 10% owner, sold 448,836 HOWL shares via open-market sales at $0.3700–$0.4000 in June 12–16.

Expected impact

Likely short-term sentiment drag; magnitude uncertain because it’s an ownership-structure/plan-driven transaction without new operating news.

Evidence & confidence

The filing is a primary-source insider/10%-owner transaction with a defined share count and price range, but it provides no new company-specific fundamentals (no guidance, trial, or deal).

Market effects

Limited sector read-through; this is a single-company ownership transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity management under a 10b5-1-like process (though the filing states no pre-arranged plan), so it may not reflect a change in outlook.

Key entities

  • Werewolf Therapeutics, Inc.

    Subject of the Form 4 insider transaction; shares sold by a 10% owner via indirect holdings.

  • RA Capital Management, L.P.

    Reporter of the Form 4; sold 448,836 shares of HOWL at $0.3700–$0.4000.

Related articles

$HOWLMed

Werewolf Therapeutics, Inc. (HOWL): Results of Operations and Financial Condition

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a06302026ex991.htm EX-99.1 Document Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates Watertown, Mass., July 31, 2026 (GLOBE NEWSWIRE) – Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL),